Scarica l'app Stockscreener
16.18
0.55%
-0.09
Dopo l'orario di chiusura:
16.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Acadia Pharmaceuticals to Present at Citi, Evercore Healthcare Conferences in December | ACAD Stock News - StockTitan
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Decreased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
When (ACAD) Moves Investors should Listen - Stock Traders Daily
Acadia Pharmaceuticals announces executive shakeup - Investing.com
Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause - MarketWatch
Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure - TipRanks
Acadia Pharmaceuticals announces executive shakeup By Investing.com - Investing.com UK
Acadia Pharma (ACAD) Chief Operating Officer to be Involuntarily Terminated Without Cause - StreetInsider.com
Acadia Pharma ticks lower amid Deutsche Bank downgrade after surge on patent win - MSN
Leerink Partnrs Issues Pessimistic Outlook for ACAD Earnings - MarketBeat
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth - MSN
Acadia Pharmaceuticals CFO sells shares worth $172,453 - Investing.com India
Acadia Pharmaceuticals CFO sells shares worth $172,453 By Investing.com - Investing.com Canada
Acadia Pharmaceuticals' COO sells $173,630 in stock By Investing.com - Investing.com Canada
FY2024 Earnings Estimate for ACAD Issued By Leerink Partnrs - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Lowered by GSA Capital Partners LLP - MarketBeat
Acadia Pharmaceuticals Grants Stock Options, RSUs to 23 New Employees in Growth Push | ACAD Stock News - StockTitan
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com
Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance
US Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals: Proving The Naysayers Wrong (NASDAQ:ACAD) - Seeking Alpha
What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings? - MarketBeat
FY2024 Earnings Estimate for ACAD Issued By HC Wainwright - MarketBeat
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates - MSN
ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Acadia Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for ACAD - Nasdaq
Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord - TipRanks
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Call Transcript - Insider Monkey
Equities Analysts Issue Forecasts for ACAD FY2027 Earnings - MarketBeat
HC Wainwright Issues Pessimistic Estimate for ACAD Earnings - MarketBeat
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St
ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Quarterly 10-Q Report - Quartzy
ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results - MarketBeat
Acadia Pharmaceuticals participates in a conference call with JPMorgan - TipRanks
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given Buy Rating at HC Wainwright - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Buy Rating from Needham & Company LLC - MarketBeat
Acadia Pharma Q3 2024 Earnings Preview - MSN
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highligh - GuruFocus.com
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Acadia: Q3 Earnings Snapshot - Houston Chronicle
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - BioSpace
Acadia Pharmaceuticals Sees Revenue Growth and Strategic Advances - TipRanks
Acadia Pharmaceuticals reports Q3 EPS , consensus 14c - TipRanks
ACADIA Pharmaceuticals Q3 2024 Earnings: EPS of $0.20 Beats Esti - GuruFocus.com
Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M - MedCity News
Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance - StreetInsider.com
Acadia Pharma sells priority review voucher for $150 million | Pharmaceutical | The Pharmaletter - The Pharma Letter
Acadia sells speedy drug review voucher for $150M - BioPharma Dive
Acadia makes $100M profit from $150M pediatric voucher sale - Fierce Biotech
Acadia lands $150M sale of rare pediatric PRV - Endpoints News
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - BioSpace
Acadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher - MarketWatch
Acadia Pharma sells Rare Pediatric Disease Priority Review Voucher for $150M - TipRanks
Acadia Pharma (ACAD) to Sell Rare Pediatric Disease Priority Review Voucher for $150M - StreetInsider.com
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):